REVENUE (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	$ 28,146	$ 29,662	$ 57,657	$ 62,427
Contract receivables, current	1,000		1,000		$ 900
Contract receivables, noncurrent	3,500		3,500		3,300
Current portion of deferred revenue, and other	8,900		8,900		9,600
Contract liabilities, revenue recognized			1,500
Contract liabilities, increase due to additional deferred sales			$ 700
Average term of underlying contracts			P6Y0M0D
Capitalized contract costs	2,600		$ 2,600		$ 2,500
Capitalized contract costs, amortization			500
Capitalized contract costs during the period			600
Core companion animal
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	24,716	26,644	49,432	53,463
Point of Care laboratory revenue:
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	16,120	15,053	32,081	28,693
Consumables
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	13,208	11,524	25,524	22,344
Sales-type leases
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	1,493	1,793	3,234	3,331
Outright instrument sales
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	1,045	1,335	2,575	2,146
Other
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	374	401	748	872
Point of Care imaging revenue:
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	5,229	4,462	10,639	10,434
Outright instrument sales
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	4,405	3,566	8,951	8,705
Service revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	558	544	1,120	1,099
Operating type leases and other
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	266	352	568	630
Other CCA revenue:
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	3,367	7,129	6,712	14,336
Other pharmaceuticals, vaccines and diagnostic tests
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	3,281	6,991	6,527	14,102
Research and development, license and royalty revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	86	138	185	234
Other vaccines and pharmaceuticals
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	3,430	3,018	8,225	8,964
Contract manufacturing
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	3,327	2,887	7,994	8,678
License, research and development
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	$ 103	$ 131	$ 231	$ 286